Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Br J Haematol ; 200(6): 740-754, 2023 03.
Artículo en Inglés | MEDLINE | ID: mdl-36354085

RESUMEN

While the bone marrow (BM) microenvironment is significantly remodelled in acute myeloid leukaemia (AML), molecular insight into AML-specific alterations in the microenvironment has been historically limited by the analysis of liquid marrow aspirates rather than core biopsies that contain solid-phase BM stroma. We assessed the effect of anthracycline- and cytarabine-based induction chemotherapy on both haematopoietic and non-haematopoietic cells directly in core BM biopsies using RNA-seq and histological analysis. We compared matched human core BM biopsies at diagnosis and 2 weeks after cytarabine- and anthracycline-based induction therapy in responders (<5% blasts present after treatment) and non-responders (≥5% blasts present after treatment). Our data indicated enrichment in vimentin (VIM), platelet-derived growth factor receptor beta (PDGFRB) and Snail family transcriptional repressor 2 (SNAI2) transcripts in responders, consistent with the reactivation of the mesenchymal population in the BM stroma. Enrichment of osteoblast maturation-related transcripts of biglycan (BGN), osteopontin (SPP1) and osteonectin (SPARC) was observed in non-responders. To the best of our knowledge, this is the first report demonstrating distinct osteogenic and mesenchymal transcriptome profiles specific to AML response to induction chemotherapy assessed directly in core BM biopsies. Detailing treatment response-specific alterations in the BM stroma may inform optimised therapeutic strategies for AML.


Asunto(s)
Médula Ósea , Leucemia Mieloide Aguda , Humanos , Médula Ósea/patología , Transcriptoma , Leucemia Mieloide Aguda/tratamiento farmacológico , Citarabina/uso terapéutico , Células de la Médula Ósea/patología , Antraciclinas/uso terapéutico , Biopsia , Microambiente Tumoral
2.
J Comput Assist Tomogr ; 38(4): 571-3, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24733001

RESUMEN

Ferumoxytol is a parenteral iron therapy that the Food and Drug Administration recently approved for the treatment of iron-deficiency anemia. The form of the iron, ultrasmall superparamagnetic iron oxide nanoparticles, causes T1, T2, and T2* shortening on magnetic resonance imaging, which can mimic hemosiderosis. We report such a case, with laboratory findings that demonstrate normal iron stores, and discuss the potential implications.


Asunto(s)
Glándulas Suprarrenales/metabolismo , Médula Ósea/metabolismo , Óxido Ferrosoférrico/farmacocinética , Hígado/metabolismo , Imagen por Resonancia Magnética/métodos , Bazo/metabolismo , Glándulas Suprarrenales/patología , Médula Ósea/patología , Reacciones Falso Positivas , Femenino , Hemosiderosis/diagnóstico , Humanos , Hierro/sangre , Hígado/patología , Pruebas de Función Hepática , Persona de Mediana Edad , Soluciones para Nutrición Parenteral/metabolismo , Bazo/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...